In today’s accelerated evolution of healthcare innovation, pharmaceutical companies are no longer measuring success solely by product lines or financial numbers. The real stakeholders – the patients, are starting to demand more: transparency, accessibility, and genuine partnership. The 2024/2025 Pharma Corporate Reputation Report, published by PatientView, provides a window into how the patient community perceives and engages with pharmaceutical companies.
The 2024/5 Corporate Reputation Survey, conducted between December 2024 and March 2025 , received a record 2,546 responses from patient groups from 100 countries. This reflects the growing voice and influence of the patient community in the healthcare ecosystem.
PatientView conducts annual surveys of patient groups across disease areas and geographies, not on scientific data or profits, but on the company’s performance in “building patient trust and partnerships.”
Reputation and trust: not synonymous
The report focuses on two main metrics: Familiarity and Partnerships. Theoretically, the two should be proportional, but the data reveals more complex phenomena.
Pfizer, for example, not only tops the list of “familiarity” (1,664 mentions), but is also the most common partner for patient groups (932 times). Roche and Novartis also showed the same double highs, demonstrating that companies that value patient engagement can not only gain visibility, but also earn trust.
AbbVie and Amgen, while well-known (1,012 vs. 790 mentions, respectively), were not mentioned in a commensurate manner with patient groups.
Small Company, Big Trust: Niche Market Strategy Success
Smaller companies or disease-specific companies, such as Vertex, UCB and Servier, are doing well, with a relatively high percentage of collaborations, although they are less recognized.
This shows that the patient community places more emphasis on “genuine interaction” rather than “brand scale”, and even with limited resources, loyalty can be earned by investing in authentic, long-term relationship building.
How should pharmaceutical companies respond?
This report not only reveals the problems, but also provides directions for improvement:
- Invest in genuine partnerships, not just marketing campaigns
- In the development and launch phases, truly listen to the patient’s voice
- Promote participation programmes that include marginal and rare disease patients
- Incorporate “Patient Trust” as a Key Performance Indicator (KPI)
summary
The reputation of pharmaceutical companies in 2024 is not based on who has the loudest voice, but who listens the most attentively. Trust and familiarity are no longer gifts, but are built through constant dialogue, cooperation and action.
Pharmaceutical companies that want to succeed in the medical field in the future must transform from product suppliers to true patient partners. As this report shows: patients are watching and waiting for your response.
Cited Data :
https://www.patient-view.com/corporate-reputation-of-pharma-2024-2025
